ABSTRACT
Histiocytic sarcoma (HS) is a rare malignant neoplasm of macrophage-dendritic cell lineage that can occur at any site. Primary base of skull involvement is exceedingly rare. We present the case of a previously healthy 56-year-old man who complained of headaches and showed localized neurologic symptoms. Magnetic resonance imaging demonstrated a hyperintense and enhancing mass involving the sphenoid bone and the clivus with an extradural component that compressed the distal pons. The differential diagnosis included chordoma or chondrosarcoma. An endoscopic trans-sphenoidal resection was performed. Microscopically, the tumor showed epithelioid and spindle morphology with atypia, mitoses, and necrosis. No osteoid, cartilaginous, or myxoid matrix was identified. By immunohistochemistry, the tumor was positive for CD68 (KP-1) and lysozyme, variably positive for CD4, CD11c, CD14, CD68 (PGM-1), CD45, and CD163, and negative for markers of epithelial, melanocytic, lymphoid, myeloid, muscle, and dendritic cell origin. Expression of PD-L1 by immunohistochemistry and BRAF V600E mutation analysis by PCR were negative. Tumor recurrence developed after radiation treatment with overwhelming progression into a largely infiltrating mass within 2 weeks with clinical deterioration, and the patient died 3 months later. To our knowledge, this represents the first case of primary HS of the clivus reported to date in the English literature, further expanding the spectrum of neoplasms seen at this site as well as the sites where HS can be seen. The overall prognosis of HS in the skull base is poor, with no standard treatment. Further research is warranted to develop effective treatment approaches, which in the future may rely on the expression of checkpoint inhibitors and/or specific molecular markers.
Subject(s)
Histiocytic Sarcoma , Central Nervous System/pathology , Cranial Fossa, Posterior/metabolism , Cranial Fossa, Posterior/pathology , Histiocytic Sarcoma/diagnosis , Histiocytic Sarcoma/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Recurrence, LocalABSTRACT
Programmed death 1 ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 IHC assays with various antibodies and cut points have been used in clinical trials across tumor types. Comparative performance characteristics of these assays have been extensively studied qualitatively but not quantitatively. Here we evaluate the use of a standardized PD-L1 Index tissue microarray (TMA) to objectively determine agreement between antibody assays for PD-L1 applying quantitative digital image analysis. Using a specially constructed Index TMA containing a panel of ten isogenic cell lines in triplicate, we tested identical but independently grown batches of isogenic cells to prove Index TMAs can be produced in large quantities and hence serve as a standardization tool. Then the Index TMAs were evaluated using quantitative immunofluorescence (QIF) to validate the TMA itself and also to compare antibodies including E1L3N, SP142 and SP263. Next, an inter-laboratory and inter-assay comparison of 5 PD-L1 chromogenic IHC assays (US Food and Drug Administration (FDA) approved and lab developed test (LDT)) were performed at 12 sites around the USA. As previously reported, the SP142 FDA assay failed to detect low levels of PD-L1 in cell lines distinguished by the other four assays. The assays for 22C3 FDA, 28-8-FDA, SP263 FDA, and E1L3N LDT were highly similar across sites and all laboratories showed a high consistency over time for all assays using this Index TMA. In conclusion, we were able to objectively quantify PD-L1 expression on a standardized Index TMA using digital image analysis and we confirmed previous subjective assessments of these assays, but now in a multi-institutional setting. We envision commercial use of this Index TMA or similar smaller version as a useful standardization mechanism to compare results between institutions and to identify abnormalities while running routine clinical samples.
Subject(s)
B7-H1 Antigen/analysis , Fluorescent Antibody Technique , Cell Line , Tissue Array AnalysisABSTRACT
Pathologists use immunohistochemistry is their day-to-day practices to assist in distinguishing site of origin of metastatic carcinomas. Here, the work-up is discussed neuroendocrine carcinomas, squamous cell carcinomas and adenocarcinomas with particular attention to tumor incident rates and predictive values of the best-performing immunohistochemical markers.
Subject(s)
Adenocarcinoma/diagnosis , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Squamous Cell/diagnosis , Neoplasms, Unknown Primary/diagnosis , Adenocarcinoma/epidemiology , Carcinoma, Neuroendocrine/epidemiology , Carcinoma, Squamous Cell/epidemiology , Humans , Immunohistochemistry , Incidence , Neoplasms, Unknown Primary/epidemiologyABSTRACT
OBJECTIVE: College of American Pathologists and the American Society of Clinical Oncology guidelines provide straightforward criteria for HER2 interpretation in breast carcinomas; however, a subset of cases present unusual diagnostic dilemmas. MATERIALS AND METHODS: Ten challenging HER2 fluorescence in situ hybridization (FISH) cases were selected for analysis. The study included a variety of problematic cases such as those with discordant immunohistochemistry (IHC) and FISH results, cases with high intratumoral variability in HER2 copy number, a case with a highly amplified clone in 5% to 10% of the tumor sample, and a case with tumor cells containing tightly clumped HER2 signals. Six high volume HER2 FISH laboratories performed and interpreted HER2 FISH (adding HER2 IHC if necessary). Interpretation strategies were discussed. RESULTS: There was 100% concordance between laboratories in 4/10 cases. Tumors with increased intratumoral variability (tumors with high variability in HER2 copy number per cell but which otherwise do not fulfill College of American Pathologists and the American Society of Clinical Oncology criteria for heterogeneity) exhibited 100% concordance in 3/4 cases, but 1 case had only 50% agreement. Low positive HER2 cases (group 1 cases with <6 average HER2 copies/cell) had 1 laboratory disagreeing with the majority in 4/4 cases, and this was the only category with discordance between IHC and FISH methodologies. All laboratories identified the case with heterogeneity and interpreted it as positive. Five of the 6 laboratories interpreted the case with tightly clustered HER2 signals as positive. CONCLUSIONS: This study offers specific observations and interpretation strategies that laboratories can use when confronted with difficult HER 2 cases. It then highlights communication strategies a laboratory may use to discuss these unusual HER2 results with the clinical team.
Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms , In Situ Hybridization, Fluorescence , Receptor, ErbB-2/biosynthesis , Adult , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Female , Humans , Middle AgedABSTRACT
Immunohistochemistry (IHC) continues to suffer from variable consistency, poor reproducibility, quality assurance disparities, and the lack of standardization resulting in poor concordance, validation, and verification. This document lists the recommendations made by the Ad-Hoc Committee on Immunohistochemistry Standardization to address these deficiencies. Contributing factors were established to be underfixation and irregular fixation, use of nonformalin fixatives and ancillary fixation procedures divested from a deep and full understanding of the IHC assay parameters, minimal or absent IHC assay optimization and validation procedures, and lack of a standard system of interpretation and reporting. Definitions and detailed guidelines pertaining to these areas are provided.
Subject(s)
Immunohistochemistry/standards , Clinical Laboratory Techniques/standards , Fixatives/standards , Histological Techniques/standards , Pathology/methods , Pathology/standardsABSTRACT
Phyllodes tumor of the breast is rare and often resembles the more commonly seen fibroadenoma at imaging and histologically. As core biopsy cannot always distinguish the two, assessing radiologic-pathologic concordance is essential to guide appropriate clinical management. We review the imaging characteristics of phyllodes tumor at mammography, ultrasound, and MRI to help the interpreting radiologist be aware of key imaging features that should alert him to the possibility of a phyllodes tumor even if not verified by initial core biopsy.
Subject(s)
Breast Neoplasms/diagnosis , Fibroadenoma/diagnosis , Phyllodes Tumor/diagnosis , Biopsy, Large-Core Needle , Diagnosis, Differential , Female , Humans , Magnetic Resonance Imaging , Mammography , Ultrasonography, MammaryABSTRACT
CDX2 is a recently cloned homeobox gene that encodes an intestine-specific transcription factor, expressed in the nuclei of epithelial cells throughout the intestine, from duodenum to rectum. While expression of CDX2 protein in primary and metastatic colorectal carcinomas has been previously documented, neither the sensitivity nor the specificity of CDX2 expression, as determined by immunohistochemistry, for colorectal adenocarcinoma has been determined. We performed an immunohistochemical survey of 476 tumors with a monoclonal antibody, CDX2-88, including 89 tumors from the colon and duodenum and 95 tumors from other gastrointestinal sites, including the esophagus, stomach, pancreatobiliary system, gastrointestinal carcinoids, and liver. CDX2 was expressed uniformly (that is, in 76-100% of tumor cells) in all but one of the evaluated colorectal and duodenal tumors. High-level expression of CDX2 was also found, however, in mucinous ovarian carcinomas and adenocarcinomas primary to the urinary bladder of which 64% and 100% were positive, respectively. Gastric, gastroesophageal, and pancreatic adenocarcinomas and cholangiocarcinomas all showed similar, heterogeneous patterns of CDX2 expression. Most tumors in each group showed CDX2 expression by a minority of cells, whereas a substantial minority of cases in each group was completely negative and a smaller minority was uniformly positive. Gastrointestinal carcinoids gave similarly varied results, but the majority (58%) was negative. Hepatocellular carcinomas showed no expression of CDX2. Only very rare examples of carcinomas of the genitourinary and gynecologic tracts, breast, lung, and head and neck showed significant levels of CDX2 expression. In this study of primary and metastatic epithelial tumors, uniform CDX2 expression is demonstrated to be an exquisitely sensitive and highly, but incompletely, specific marker of intestinal adenocarcinomas. Compared with villin, a previously described marker of GI adenocarcinomas, CDX2 demonstrated superior sensitivity and comparable specificity. CDX2 expression can be seen, however, in selected non-GI adenocarcinomas such as mucinous ovarian carcinomas and adenocarcinomas of the urinary bladder.
Subject(s)
Adenocarcinoma/metabolism , Carrier Proteins/metabolism , Gastrointestinal Neoplasms/metabolism , Homeodomain Proteins/metabolism , Microfilament Proteins/metabolism , Adult , CDX2 Transcription Factor , Fetus , Humans , Immunohistochemistry , Intestines , Sensitivity and Specificity , Trans-ActivatorsABSTRACT
Identification of myoepithelial cells using antibodies to cytoskeletal proteins, such as smooth muscle myosin heavy chain (SMM-HC) and calponin, can play an important role in distinguishing invasive carcinoma from its histologic mimics. However, antibodies to these proteins may also cross-react with stromal myofibroblasts and vascular smooth muscle cells. It has recently been demonstrated that myoepithelial cells express the nuclear protein, p63, a member of the p53 gene family. We compared the patterns of reactivity of antibodies with p63, calponin, and SMM-HC on 85 breast lesions, including 11 cases of sclerosing adenosis, 33 cases of ductal carcinoma in situ, including 10 that showed microinvasion, 6 cases of lobular carcinoma in situ, and 35 cases of infiltrating ductal carcinoma. All three antibodies were positive on the vast majority of myoepithelial cells in all cases. A small minority of cases showed focal gaps in the revealed myoepithelial cell layer, reflected in discontinuous positive immunostaining around noninvasive epithelial nests (including ductal carcinoma in situ). No case showed p63 expression by myofibroblasts or vascular smooth muscle cells, whereas myofibroblasts expressed, in 8% and 76% of cases, SMM-HC and calponin, respectively. Although no tumor cell reactivity was noted with antibodies to calponin or SMM-HC, tumor cells in 11% of cases showed at least focal p63 expression. And although antibodies to p63 offer excellent sensitivity and increased specificity for myoepithelial detection relative to antibodies to calponin and SMM-HC, they have the following diagnostic limitations: 1) they occasionally demonstrate an apparently discontinuous myoepithelial layer, particularly around ductal carcinoma in situ, and 2) they react with a small but significant subset of breast carcinoma tumor cells. p63 may represent a myoepithelial marker that can complement or replace SMM-HC and/or calponin in the analysis of difficult breast lesions.
Subject(s)
Breast Neoplasms/chemistry , Calcium-Binding Proteins/analysis , Carcinoma/chemistry , Membrane Proteins , Myosin Heavy Chains/analysis , Phosphoproteins/analysis , Trans-Activators/analysis , Biomarkers, Tumor/analysis , Breast Neoplasms/pathology , Carcinoma/pathology , Carcinoma in Situ/chemistry , Carcinoma in Situ/pathology , Carcinoma, Ductal, Breast/chemistry , Carcinoma, Ductal, Breast/pathology , Carcinoma, Intraductal, Noninfiltrating/chemistry , Carcinoma, Intraductal, Noninfiltrating/pathology , Carcinoma, Lobular/chemistry , Carcinoma, Lobular/pathology , DNA-Binding Proteins , Diagnosis, Differential , Female , Fibrocystic Breast Disease/chemistry , Fibrocystic Breast Disease/pathology , Genes, Tumor Suppressor , Humans , Immunoenzyme Techniques/methods , Microfilament Proteins , Muscle, Smooth/chemistry , Neoplasm Invasiveness , Neoplasm Proteins/analysis , Sensitivity and Specificity , Smooth Muscle Myosins/analysis , Transcription Factors , Tumor Suppressor Proteins , CalponinsABSTRACT
Carcinomas of ovarian surface epithelial origin can arise from, and often present at, extraovarian sites. There are few available markers for the positive identification of carcinomas of ovarian surface epithelial origin, which might aid in distinguishing them from metastatic carcinomas, such as of breast, colon, or lung origin. Recently, the Wilms tumor gene product (WT-1) has been shown to be expressed in ovarian surface and mesothelial epithelium. We tested the hypothesis that WT-1 would be a sensitive and specific marker of ovarian surface epithelium carcinomas. An archived series of 116 ovarian carcinomas (57 serous [43 ovarian, 14 extraovarian], 31 mucinous, 15 clear cell, 13 endometrioid), 118 breast carcinomas, 46 colonic carcinomas, and 45 nonsmall cell lung cancers were selected. A polyclonal antibody to the WT-1 gene product was applied to deparaffinized, formalin-fixed tissue sections after epitope retrieval. Fifty-two of 57 (93%) serous carcinomas of ovarian surface epithelial origin were WT-1-positive, in a nuclear pattern, with virtually all the tumor cell population positive in the majority of cases. None of the mucinous, clear cell, or endometrioid ovarian cancers were positive, and only 8 of 118 breast, 0 of 46 colonic, and 0 of 45 lung nonsmall cell carcinomas were WT-1-positive. These findings demonstrate that WT-1 is a highly sensitive and specific marker of serous carcinomas of ovarian surface epithelial origin (both ovarian and extraovarian). These results also contradict recent reports demonstrating WT-1 expression in both breast and lung carcinomas.
Subject(s)
Cystadenocarcinoma, Serous/pathology , Ovarian Neoplasms/pathology , WT1 Proteins/analysis , Adenocarcinoma, Mucinous/chemistry , Adenocarcinoma, Mucinous/pathology , Antigens, Neoplasm/analysis , Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Cystadenocarcinoma, Serous/chemistry , Cystadenocarcinoma, Serous/diagnosis , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/diagnosis , Sensitivity and SpecificityABSTRACT
While historically detection of premelanosomes by electron microscopic studies was the only means possible of confirming melanocytic lineage of a neoplastic process, advances in the field of immunohistochemistry have allowed for accurate and reliable diagnosis using antibodies to 1 of a number of melanocyte-restricted proteins. S-100 was the first such marker exploited by immunohistochemistry; subsequently, the HMB45 monoclonal antibody to gp100 became widely used as a sensitive and specific melanocytic marker. More recently, antibodies to other melanocytic proteins have become available, inciuding the MART-1 gene product and microphthalmia transcription factor. This article provides a brief overview of these markers in terms of their specificity and sensitivity and offers a discussion of tumors with partial melanocytic differentiation.
Subject(s)
Biomarkers, Tumor/analysis , Immunohistochemistry/methods , Melanoma/chemistry , Humans , Melanoma/secondary , Neoplasm Proteins/analysis , Sensitivity and SpecificityABSTRACT
CONTEXT: Testing for HER-2 oncogene in breast cancer has increased because of its role as a prognostic and predictive factor. Some advocate gene testing by fluorescence in situ hybridization (FISH) vs protein testing by immunohistochemistry as the method which most accurately evaluates and predicts response to the anti-HER-2 antibody, trastuzumab. However, critical examination of FISH on a screening basis has yet to be performed. OBJECTIVES: To determine the correlation between FISH and immunohistochemistry results by determining HER-2/neu gene status on tumor sections with indeterminate immunohistochemistry results (2+ score), confirm gene amplification on tumor sections with positive results (3+ score), and verify gene status on tumor sections with negative results (0 or 1+ score). DESIGN, SETTING, AND PATIENTS: A quality control and quality assurance program for HER-2 testing by FISH, which used tumor specimens from 2963 patients (median age, 56 years) with breast cancer received from 135 hospitals and cancer centers in 29 states, was performed at a reference laboratory from January 1, 1999, to May 15, 2003. Every specimen evaluated by FISH was parallel tested with immunohistochemistry tests. MAIN OUTCOME MEASURES: With FISH as the presumed standard testing method, the positive and negative predictive values and sensitivity and specificity of immunohistochemistry were calculated. RESULTS: A total of 3260 clinical HER-2 tests by FISH were performed on 2963 serially referred breast cancer specimens. Of these, 2933 tests were successful and 2913 breast cancer specimens had both FISH and immunohistochemistry results available. With FISH as the standard testing method, the positive predictive value of positive immunohistochemistry score (3+) was 91.6%, and the negative predictive value of negative immunohistochemistry score (0 or 1+) was 97.2%. The sensitivity of immunohistochemistry tests, including tumor sections with scores of 2+ or 3+, was 92.6% and the specificity of immunohistochemistry tests with scores of 3+ was 98.8%. The FISH test had a significantly higher failure rate (5% vs 0.08%) and reagent cost (140 dollars vs 10 dollars), and longer testing (36 hours vs 4 hours) and interpretation times (7 minutes vs 45 seconds) vs immunohistochemistry tests. CONCLUSIONS: A testing algorithm for HER-2 determination is most efficient by using immunohistochemistry as the method of choice, with FISH performed for cancers with indeterminate results (2+ score). Successful quality control and quality assurance programs are a prerequisite for such approaches.
Subject(s)
Breast Neoplasms/genetics , Genes, erbB-2 , Immunohistochemistry , In Situ Hybridization, Fluorescence , Receptor, ErbB-2/metabolism , Adult , Aged , Aged, 80 and over , Algorithms , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Genetic Testing/methods , Genetic Testing/standards , Humans , Immunohistochemistry/standards , In Situ Hybridization, Fluorescence/standards , Middle Aged , Predictive Value of Tests , Quality Control , Sensitivity and Specificity , TrastuzumabABSTRACT
While it is tempting to think of the results of laboratory tests as quantitative, reproducible and accurate, many tests in fact have embedded variables that could lead to inconsistency and sometimes false reporting of results. Tissue-based testing of HER-2/neu in breast cancer represents an example of the latter. This article discusses the available technologies for HER-2/neu testing with some of the sources of testing errors.
Subject(s)
Breast Neoplasms/genetics , Genes, erbB-2 , Genetic Testing/standards , Practice Guidelines as Topic , Education, Continuing , Gene Amplification , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Reproducibility of Results , United StatesSubject(s)
Breast Neoplasms/diagnosis , Practice Guidelines as Topic , Receptor, ErbB-2/analysis , Female , HumansSubject(s)
B7-H1 Antigen/metabolism , Biomarkers, Tumor/analysis , Genital Neoplasms, Female/diagnosis , Genital Neoplasms, Female/drug therapy , Neoplasms/diagnosis , Neoplasms/drug therapy , Aged , Carcinosarcoma/diagnosis , Carcinosarcoma/drug therapy , Carcinosarcoma/pathology , Drug Delivery Systems , Female , Genital Neoplasms, Female/economics , Humans , Immunohistochemistry , Middle Aged , Neoplasms/economicsABSTRACT
Among the core principles in the practice of immunohistochemistry is the use of carefully chosen marker panels. Choosing an appropriate panel of antibodies is predicated on a sound differential diagnosis that is based on detailed examination of hematoxylin and eosin-stained slides. The panel should contain antibodies designed to be immunoreactive in the most likely disease(s) in the differential as well as selected negative markers. In addition, the importance of detailed historical and clinical information in constructing the differential diagnosis and panel selection cannot be understated. Two cases from the Case Presentation sessions of the 5th Annual Retreat for Applied Immunohistochemistry and Molecular Pathology are summarized to illustrate these points. The first case is that of metastatic well-differentiated neuroendocrine tumor (carcinoid) tumor presenting as a breast mass. The second is that of a squamous cell carcinoma of the lung mimicking a tumor with admixed glandular differentiation by entrapment and disruption of bronchial glands. Application of a select immunohistochemistry panel in light of the differential diagnosis and importance of making a specific diagnosis are discussed.
Subject(s)
Carcinoma/diagnosis , Carcinoma/pathology , Immunohistochemistry , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Antibodies/metabolism , Antigens, Neoplasm/immunology , Biomarkers, Tumor , Carcinoma/immunology , Diagnosis, Differential , Florida , Humans , Immunohistochemistry/methods , Immunohistochemistry/trends , Lung Neoplasms/immunology , Pathology, Molecular , Prognosis , Staining and LabelingSubject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , Breast Neoplasms/diagnosis , Immunohistochemistry , In Situ Hybridization, Fluorescence , Receptor, ErbB-2/analysis , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , DNA, Neoplasm/analysis , Female , Gene Expression Regulation, Neoplastic , Humans , Predictive Value of Tests , RNA, Neoplasm/analysis , Receptor, ErbB-2/genetics , Sensitivity and Specificity , Trastuzumab , Treatment Outcome , Up-RegulationABSTRACT
Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of "false-negative" results worldwide. Standardized testing is only possible after all aspects of ER testing--preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the "ad-hoc committee" of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.